Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970664 | 0.98 | TDP1 (0.61) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| Ethylene SCHEMBL8002940 | 0.89 | TDP1 (0.68) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL205788 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL3870579 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL1555414 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL15512282 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL15512375 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL15512201 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL15512622 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL15512301 | 0.88 | TDP1 (0.73) | TDP1LMNAMAPK1HIF1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | NAKAJIMA MOTOWO | 2005-10-20 | — | — | US | disclosed |
| EP-1485131-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003075959-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-6500983-B2 | FOR THERAPY OF DISEASES OR CONDITIONS MEDIATED BY OVER-PRODUCTION OF OR OVER-RESPONSIVENESS TO TUMOR NECROSIS FACTOR (TNF) | NOVARTIS AG (CH) | 2002-12-31 | — | — | US | disclosed |
| EP-0929517-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| US-20020038045-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-03-28 | — | — | US | disclosed |
| EP-0929517-A1 | HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014424-A1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| EP-0315899-B1 | THIEN-3-YL AZO DYES | BASF Aktiengesellschaft (DE) | 1993-04-07 | — | — | EP | disclosed |
| EP-0315898-B1 | ISOTHIAZOLE AZO DYES | BASF Aktiengesellschaft (DE) | 1993-01-20 | — | — | EP | disclosed |
| US-4994564-A | Dyeing synthetic fibers in shades of red, yellow | BASF AKTIENGESELLSCHAFT (DE) | 1991-02-19 | — | — | US | disclosed |
| US-4929720-A | YELLOW DYES FOR SYNTHETIC FIBERS | BASF AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
| EP-0315898-A2 | Isothiazole azo dyes | BASF Aktiengesellschaft (DE) | 1989-05-17 | — | — | EP | disclosed |
| US-4107192-A | Antimicrobial esters of allphatic diols | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1978-08-15 | — | — | US | disclosed |
| US-4074058-A | Antimicrobial esters of aliphatic diols | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1978-02-14 | — | — | US | disclosed |
| US-4024164-A | BENZOIC ACID, ANTIMICROBIAL AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | MMP3, TIMP3, MMP25 | TDP1 704/4885LMNA 1706/4885MAPK1 2692/4885 |
| US-20020038045-A1 | Hydroxamic acid derivatives | TNF, HCAR2, HCAR1 | TDP1 1663/4885LMNA 4203/4885MAPK1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.